论文部分内容阅读
目的探讨高危骨髓增生异常综合征(MDS)的临床特点和实验研究,观察联合化疗对高危MDS的疗效,对治疗效果进行分析。方法应用联合化疗方案对31例高危MDS患者进行治疗,结合实验室检查结果分析其疗效。结果 31例高危MDS患者,化疗后完全缓解12例(38.7%),该12例患者中位生存期为18个月。19例未缓解者中位生存期为7个月。化疗主要不良反应为骨髓抑制期感染,少数出现肝功能异常和心肌损害。结论联合化疗对高危MDS患者有一定疗效,需加强对症支持治疗。
Objective To investigate the clinical characteristics and experimental study of high risk myelodysplastic syndrome (MDS) and to observe the curative effect of combined chemotherapy on high-risk MDS and to analyze the therapeutic effect. Methods Thirty-one patients with high-risk MDS were treated with combination chemotherapy regimen. The curative effect was analyzed according to the laboratory test results. Results In 31 high-risk MDS patients, complete remission was achieved in 12 patients (38.7%) after chemotherapy. The median survival time of these 12 patients was 18 months. The median survival of 19 non-remission patients was 7 months. The main adverse reactions of chemotherapy for myelodysplastic infection, a small number of liver dysfunction and myocardial damage. Conclusions Combined chemotherapy has certain effect on patients with high risk MDS, need to strengthen symptomatic and supportive treatment.